Association of host, agent and environment characteristics and the duration of incubation and symptomatic periods of norovirus gastroenteritis

T. DEVASIA[1], B. LOPMAN[2], J. LEON[3] AND A. HANDEL[1]*

[1] *Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, USA*
[2] *Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA*
[3] *Hubert Department of Global Health, Emory University, Atlanta, GA, USA*

SUMMARY

We analysed the reported duration of incubation and symptomatic periods of norovirus for a dataset of 1022 outbreaks, 64 of which reported data on the average incubation period and 87 on the average symptomatic period. We found the mean and median incubation periods for norovirus to be 32·8 [95% confidence interval (CI) 30·9–34·6] hours and 33·5 (95% CI 32·0–34·0) hours, respectively. For the symptomatic period we found the mean and median to be 44·2 (95% CI 38·9–50·7) hours and 43·0 (95% CI 36·0–48·0) hours, respectively. We further investigated how these average periods were associated with several reported host, agent and environmental characteristics. We did not find any strong, biologically meaningful associations between the duration of incubation or symptomatic periods and the reported host, pathogen and environmental characteristics. Overall, we found that the distributions of incubation and symptomatic periods for norovirus infections are fairly constant and showed little differences with regard to the host, pathogen and environmental characteristics we analysed.

Key words: Norwalk agent and related viruses.

INTRODUCTION

Noroviruses are a major cause of gastroenteritis [1–3]. There are an estimated 19–21 million norovirus cases and 56 000–71 000 hospitalizations in the United States per year [4–6]. Noroviruses frequently result in outbreaks and cause ~50% of all epidemic gastroenteritis worldwide [7]. Noroviruses are also the most common cause of foodborne disease outbreaks in the United States [8]. Outbreaks affect all age groups and commonly occur in nursing homes, hospital wards, daycare centres, schools, cruise ships and restaurants. The elderly, young children, travellers, and the immunocompromised are most vulnerable to higher incidence or severe outcomes from infection [3]. With the decrease in severe rotavirus infections in children as a result of rotavirus vaccination, norovirus is now the most frequent cause of paediatric gastroenteritis requiring medical attention in the United States [9]. Globally, norovirus is estimated to account for around 18% of both community- or clinic-based gastroenteritis cases and emergency department- or hospital-based cases [10, 11].

Despite the high frequency of outbreaks and the substantial public health burden, there are still important gaps in our understanding of fundamental aspects of norovirus infection and transmission dynamics.

* Author for correspondence: Professor A. Handel, Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA 30602, USA.
(Email: ahandel@uga.edu)

One gap is the dearth of studies based on mathematical and computational models that can be used to evaluate the effectiveness of specific interventions. Such modelling studies have been successfully applied to other infectious diseases such as measles, influenza, HIV, malaria, and tuberculosis [12–15]. In anticipation of norovirus vaccines, which are currently in the pipeline [16], the development of realistic mathematical models that can help to better understand transmission dynamics and the impact of interventions such as vaccination would be important.

Reliable mathematical models require accurate estimates for parameters governing the natural history of the disease and its infection and transmission dynamics. While such values are often reported in the literature, they are not always based on hard, quantitative and reliable estimates [17]. Systematic studies that determine estimates for parameters based on multiple sources of data are useful [18–20]. For norovirus, accurate estimates for its incubation period have previously been established [20]. Here, we set out to also estimate the duration of the symptomatic period. In addition, we analyse whether the average incubation and symptomatic periods are associated with certain host, agent and environmental characteristics.

METHODS

Data collection

Data on the duration of the incubation and symptomatic periods of norovirus gastroenteritis were abstracted as reported in detail elsewhere [21, 22]. Briefly, published reports of human norovirus outbreaks with norovirus presence in stool confirmed with RT–PCR were systematically collected. Data from all of these outbreaks were abstracted according to as many as 74 different variables, including genotype, outbreak setting, suspected route of transmission, number of cases, and at-risk population size. Detailed descriptions of the dataset and our previous analyses are available in [21, 22]. We have since continued to update the dataset by adding further outbreaks following the same approach as described for the original dataset. The current number of catalogued outbreaks in our dataset is 1022; outbreak years are from 1983 to 2010. The dataset contains minimum, maximum, median, and mean values for the incubation and symptomatic periods for each outbreak where it was reported. These are the main outcomes of interest for this analysis. Most studies reported these periods in hours. When these periods were reported in days, we converted to hours by multiplying the periods in days by 24. This approximation likely leads to an unavoidable increase in values that are multiples of 12 h, since most studies reporting in days rounded to the closest half-day.

Data analysis

Confidence intervals (CIs) for incubation and symptomatic periods were computed through resampling of the data 100 000 times via non-parametric bootstrapping [23]. For investigation of continuous predictors, we fitted linear models. For categorical predictors, we computed 95% CIs through non-parametric bootstrapping. The absence of overlap in the CIs provides a conservative measure of statistically significant differences [24]. Visual inspection of the data suggested that tests based on a parametric assumption of normality could also be justified. We therefore also used parametric tests of significance, namely t tests (for two groups) or ANOVA (for multiple groups), which provide more sensitive measures compared to CIs of detecting potential differences between groups [24]. As shown in the Results section, assessing the non-parametric CIs and the results from the direct parametric statistical analyses lead to very similar results. A final regression model with all predictors was also fit [25]. All analyses were done in R version 3.0·1 [26] using additional functionality from the package boot.

RESULTS

Distribution of the incubation period

Of the 1022 outbreaks in our dataset, 73 reported a minimum value for the incubation period, 71 a maximum value, 48 a median and 21 a mean value (five reported both mean and median). We investigated the distribution of the reported values for the mean and median and found them to be rather similar (data not shown). We therefore decided to not distinguish between mean and median in subsequent analyses and pool them. We refer to those pooled values by the generic term 'average'. For those five outbreaks where both mean and median were reported, we arbitrarily used the mean value. Our overall results do not change if the median is used instead (data not shown).

Figure 1*a* shows the distributions of minimum, maximum and mean/median values of the incubation period. For 51 outbreaks in our dataset, we had complete information for both minimum and maximum duration of the incubation period, as well as either mean or median of the incubation period. Values for those outbreaks are shown in Figure 1*b*.

The mean (95% CI) across all outbreaks for the average (mean or median) duration of the incubation period were 32·8 h (30·9–34·6 h). The median (95% CI) were 33·5 h (32·0 –34·0 h).

The mean (95% CI) across all outbreaks for the reported minimum duration of the incubation period were 14·9 h (12·8–17·0 h). The median (95% CI) were 14·5 h (12·0–18·0 h).

The mean (95% CI) across all outbreaks for the maximum duration of the incubation period were 57·2 h (52·2–62·9 h). The median (95% CI) were 54·0 h (48·0–60·0 h).

Distribution of the symptomatic period

Of the outbreaks in our dataset, 90 reported a minimum value for the symptomatic period, 90 a maximum value, 59 a median and 31 a mean value (three reported both mean and median). As done for the incubation period, we again pooled mean and median and if both values were present, we used the mean. For one outbreak, a value for the maximum duration of the symptomatic period of 1248 h (52 days) was reported several times larger than the second highest value of 384 h. We checked the original reference, which indeed reported 52 days as the upper range without further comment [27]. While long-term symptoms and shedding have been reported [28] and are likely an important driver of transmission in some settings, we decided to treat this value as an outlier and remove it for the purpose of computing the mean and 95% CI of the maximum duration reported below.

Figure 1*c* shows the distributions of minimum, maximum and mean/median values of the symptomatic period. For 68 outbreaks in our dataset, we had complete information for minimum, maximum and either mean or median of the incubation period. Values for those outbreaks are shown in Figure 1*d*.

The mean (95% CI) across all outbreaks for the average (mean or median) duration of the incubation period were 44·7 h (39·0–52·1 h). The median (95% CI) were 43·0 h (36·0–48·0 h).

The mean (95% CI) across all outbreaks for the reported minimum duration of the incubation period were 16·9 h (14·1–19·8 h). The median (95% CI) were 17·0 h (11·0–24·0 h).

The mean (95% CI) across all outbreaks for the maximum duration of the incubation period were 130·4 h (114·0–147·9 h). The median (95% CI) were 105·5 h (96·0–127·5 h).

Association of incubation period with host, pathogen and environmental characteristics

For the 64 outbreaks for which we have information on either mean or median duration of the incubation period, we analysed whether the duration of the incubation period was associated with predictors of interest in our dataset. We found no statistically significant association with any of the following predictors: healthcare setting, food service setting, hemisphere, season of outbreak, virus genotype, presence of other pathogens, or mode of transmission (Table 1). Analysis of outbreaks that explicitly reported vomiting *vs.* those that did not mention vomiting suggested differences between incubation periods that were marginally significant ($P = 0·04$, Table 1). However, only five outbreaks did not report vomiting, and lack of reporting vomiting does not necessarily indicate that it did not occur. Therefore, this difference may not be meaningful. A linear regression analysis of the impact of average age on incubation period for those outbreaks that reported both variables ($N = 32$ outbreaks) suggested that there was no significant variability based on age ($P = 0·467$). A linear regression between the proportion of infected (i.e. attack 'rate') and incubation period also found no correlation ($N = 51$, $P = 0·644$). A final linear regression between the incubation period and all predictor variables was performed on the $N = 24$ entries for which information for all predictors was available. The only significant predictor for this analysis with all predictors included was age ($P = 0·04$), despite age not showing a statistically significant association in a univariate analysis.

Association of symptomatic period with host, pathogen and environmental characteristics

We repeated the analysis performed in the previous section for the 87 outbreaks for which information on either mean or median duration of the symptomatic period was available. We found no statistically

Fig. 1. Distribution of minimum, mean/median and maximum incubation and symptomatic periods. (*a*) All values for the incubation period available for any of the outbreaks in the database. The horizontal line indicates the mean. (*b*) Values for the incubation period for outbreaks for which both minimum and maximum and either mean or median (or both) are available. (*c*) and (*d*) are same as (*a*) and (*b*) for the symptomatic period. In (*b*) and (*d*), the x-axis denotes outbreaks, which are shown in no specific order.

significant association between the duration of the symptomatic period with reported vomiting, healthcare setting, food service setting, season of outbreak, virus genotype, or presence of other pathogens (Table 1). Grouping according to healthcare setting and food service setting showed noticeable differences, but those did not reach the 5% significance level. Similarly, outbreaks caused by the GII.4 strain had noticeably longer symptomatic periods, but again this did not reach statistical significance. A statistically significant association between main mode of transmission and duration of symptomatic period was found ($P = 0.003$). Foodborne transmission was associated with a shorter symptomatic period compared to other modes of transmission (Table 1). Hemisphere also showed a small statistically significant difference, with shorter symptomatic periods in the Southern hemisphere ($P = 0.02$, Table 1). A linear regression analysis of the impact of average age on symptomatic period for those outbreaks that report both quantities ($N = 45$ outbreaks) suggested that there was no

significant variability based on age ($P = 0.131$). A linear regression between proportion of infected (i.e. attack 'rate') and symptomatic period also found no correlation ($N = 72$, $P = 0.316$). A final linear regression between the symptomatic period and all predictor variables was performed on the $N = 26$ entries for which information for all predictors was available. None of the predictors was significant.

DISCUSSION

Based on the analysis of an abstracted dataset of norovirus outbreaks, we reported the average of the incubation period for norovirus to be ∼33 h. This is similar to another recent estimate of ∼29 h [20]. Our slightly larger value might be due to the fact that we used summary (median or mean) values reported in the original articles, rather than individual-level data, so some of our data may have been skewed by outlying individual values. Moreover, we did not try to adjust for potential censoring and inexact reporting, as was done in

Table 1. *Average (either mean or median, depending on what was reported) incubation and symptomatic periods for different host, pathogen and environmental characteristics*

	Incubation period		Symptomatic period	
	No. of outbreaks	Average (95% CI) (h)	No. of outbreaks	Average (95% CI) (h)
Vomiting reported	59	32·3 (30·3–34·1)*	82	44·2 (38·5–51·7)
Vomiting not reported	5	39·0 (35·2–43·4)*	5	53·8 (30·8–90·7)
Healthcare setting	2	25·0 (7·0–43·0)	13	65·8 (37·0–106·7)
Non-healthcare setting	62	33·1 (31·3–34·7)	74	41·0 (37·2–45·0)
Food service setting	42	32·3 (30·0–34·4)	35	38·4 (33·6–43·6)
Non-food service setting	22	33·8 (30·3–36·8)	52	49·0 (40·3–60·6)
Northern hemisphere	45	33·4 (31·3–35·4)	70	47·0 (40·2–56·0)*
Southern hemisphere	19	31·3 (27·4–34·7)	16	34·4 (28·5–40·3)*
Spring season	13	30·4 (25·2–34·5)	19	39·6 (30·7–48·4)
Summer season	16	32·4 (27·4–36·5)	16	44·5 (35·8–54·4)
Autumn season	16	33·3 (30·3–36·1)	25	48·1 (35·0–69·5)
Winter season	19	34·3 (32·4–36·8)	25	47·0 (39·2–56·6)
GII.4 virus	8	35·6 (32·0–39·8)	22	57·5 (38·9–83·5)
Non-GII.4 virus	56	32·4 (30·3–34·3)	65	40·4 (36·7–44·2)
GI virus	21	34·6 (32·9–36·6)	22	38·5 (31·4–45·9)
GII virus	34	33·5 (31·6–35·4)	50	48·0 (39·1–60·0)
Other pathogen present	12	34·6 (30·8–40·0)	15	38·5 (29·1–50·7)
No other pathogen present†	27	33·5 (30·6–35·6)	35	48·0 (36·8–63·2)
Foodborne transmission‡	51	33·6 (32·0–35·0)§	49	35·8 (31·6–40·2)*
Person-to-person transmission‡	1	7·0 (n.a.)	16	68·5 (41·8–108·2)*
Environmental transmission‡	9	35·9 (32·1–40·4)	13	49·6 (41·6–58·6)*

CI, Confidence interval; n.a., not available.

* Indicates statistical significance at the <5% level for different categories within groups based on *t* test or ANOVA.

† If we assume that outbreaks for which no information was given correspond to absence of other pathogen, this category has $N = 52$ (incubation period) and $N = 72$ (symptomatic period), again no significant difference compared to presence of other pathogen.

‡ Main route of transmission if multiple routes were indicated.

§ *t* test between foodborne and environmental transmission was not significant. Person-to-person transmission not tested since only one value is available.

Background shading indicates grouping of predictor variables for statistical analysis.

[20]. It is reassuring that despite those differences, the estimates were rather close.

The average minimum and maximum duration of the incubation period across outbreaks was found to be about 15 h and 55 h. This is a somewhat tighter range than the values of about 10 h and 72 h at which 5% and 95% of individuals are estimated to report symptoms following infection [20]. Given the different methodology (individual patient data *vs.* comparison across outbreaks) and different values that were measured, complete agreement was not expected, but the values are again similar.

For the average symptomatic period, we reported an estimate of ~44 h. The average minimum and maximum duration of the incubation period across outbreaks was found to be about 17 h and 120 h, respectively. This rather wide range between the minimum and maximum symptomatic period highlights that many individuals recover quickly, while a small group may be ill for longer, ~5 days, based on our synthesis. Quantifying this range is important for detailed, individual-based computational models that consider the individual-level variation.

Mathematical or computational modelling studies need reliable estimates for important parameters such as the duration of the incubation and symptomatic periods (which often, but not always, can be assumed to coincide with the latent and infectious periods). Further, it is important to know how these parameters might depend on the situation to which the model is applied. For instance, influenza in children is longer than in adults [29], therefore depending on which population a model describes, the parameters need to be chosen appropriately. There is some

evidence that the duration of norovirus gastroenteritis is longer for young children [30] and patients affected in healthcare outbreaks [31]. Therefore, we investigated the variability of the incubation and symptomatic periods based on host, agent and environment characteristics. Our investigation of the variability of these quantities found that there was little difference between the average incubation or symptomatic periods and any of the host, pathogen and environmental characteristics we considered.

Only a few predictors lead to marginally statistically significant differences. For the incubation period, the reported presence or absence of vomiting was found to have a statistically significant association. However, only five outbreaks did not report vomiting, and we do not know if lack of such reporting properly indicated absence of vomiting. It is therefore unclear whether this statistically significant difference is meaningful.

While age did not show a significant association with duration of the incubation period in a univariate analysis, it was the only significant predictor in a multiple regression model, although the significance was marginal. This difference in result might be due to the fact that for the multiple regression analysis, we only included the subset of outbreaks for which information on all predictors was available ($N = 24$), while the univariate analysis of age was performed on 32 outbreaks. The finding that a shorter incubation period is associated with younger age is not surprising. The caveat to this finding, as to all of our results, is that the unit of analysis is not individual patients but outbreaks.

For the symptomatic period, an outbreak occurring in the Northern hemisphere was associated with a longer duration of symptoms; however, the significance was marginal and we cannot think of a biological reason that would support this statistical finding. Given that we performed a number of comparisons here, and did not use any multiple-corrections test, it is expected that a chance significant difference at the 5% level occasionally occurs.

Foodborne transmission was associated with a significant reduction in the symptomatic period compared to other routes of transmission in a univariate analysis. However, this significance was not found in a multi-predictor analysis.

We did observe a longer, but non-significant, duration of the symptomatic period in vulnerable populations (i.e. those affected in healthcare settings). While this did not reach statistical significance for our

dataset, it agrees with previous findings [31] and might be worth further investigation.

Overall, we interpret our analysis of host, pathogen and environment factors to indicate that the average duration of incubation and symptomatic period is rather robust and varies little with changes in host, pathogen and environmental conditions.

The current analysis has several limitations. The most important is the fact that our unit of analysis is individual outbreaks and not individual persons. This means ecological fallacies might be present. For our particular study, it means that potentially existing associations between the predictors and outcomes we analysed might exist at the individual person level, but we were not able to detect them with an analysis that uses outbreaks as unit of analysis.

Further, our data might be biased owing to the fact that all outbreaks we analysed were published in the literature. This was clearly not a representative sample of all norovirus outbreaks, as evidenced by the fact that outbreaks in healthcare settings are a minority of the reported outbreaks, even though this is known to be the most common setting [8, 32]. Given that we did not find differences according to outbreak setting, this might not have biased the overall results. However, our sample size for some of the settings was small, so a definite conclusion cannot be drawn. Furthermore, only a fraction of the outbreaks reported information on the incubation and symptomatic periods. It could be that studies reporting such information are not representative of the whole dataset.

Another caveat to the results comes from potential rounding in the original studies. For instance while values for the incubation period duration were usually reported in hours, often the numbers appeared as though they were rounded. Specifically multiples of 12 h (e.g. values of 24, 36, 48 h) seemed to occur frequently, suggesting potential rounding to those numbers by the authors of the original reports. While this rounding likely occurred in a random fashion and is therefore unlikely to bias our estimates, it leads to some additional uncertainty in the precision of the estimates.

Despite these limitations, we believe that the estimation of the incubation and symptomatic periods and their ranges done here is a useful contribution towards our understanding the dynamics of norovirus transmission and will be a useful input for future norovirus transmission models. Such models can be used to evaluate the potential of intervention strategies, including vaccination.

DECLARATION OF INTEREST

None.

REFERENCES

1. **Moreno-Espinosa S, Farkas T, Jiang X.** Human caliciviruses and pediatric gastroenteritis. *Seminars in Pediatric Infectious Diseases* 2004; **15**, 237–245.
2. **Karst SM.** Pathogenesis of noroviruses, emerging RNA viruses. *VIRUSES–BASEL* 2010; **2**, 748–781.
3. **Glass RI, Parashar UD, Estes MK.** Norovirus gastroenteritis. *New England Journal of Medicine* 2009; **361**, 1776–1785.
4. **Lopman BA, et al.** Increasing rates of gastroenteritis hospital discharges in US adults and the contribution of norovirus, 1996–2007. *Clinical Infectious Diseases* 2011; **52**, 466–474.
5. **Scallan E, et al.** Foodborne illness acquired in the United States – major pathogens. *Emerging Infectious Diseases* 2011; **17**, 7–15.
6. **Hall AJ, et al.** Norovirus disease in the United States. *Emerging Infectious Diseases* 2013; **19**, 1198–1205.
7. **Widdowson M-A, Monroe SS, Glass RI.** Are noroviruses emerging? *Emerging Infectious Diseases* 2005; **11**, 735–737.
8. **Hall AJ, et al.** Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States. *Emerging Infectious Diseases* 2013; **19**, 1305–1309.
9. **Payne DC, et al.** Norovirus and medically attended gastroenteritis in U.S. children. *New England Journal of Medicine* 2013; **368**, 1121–1130.
10. **Patel MM, et al.** Systematic literature review of role of noroviruses in sporadic gastroenteritis. *Emerging Infectious Diseases* 2008; **14**, 1224–1231.
11. **Ahmed SM, et al.** Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. *Lancet Infectious Diseases* 2014; **14**, 725–730.
12. **Grassly NC, Fraser C.** Mathematical models of infectious disease transmission. *Nature Reviews Microbiology* 2008; **6**, 477–487.
13. **Keeling M, Rohani P.** *Modeling Infectious Diseases in Humans and Animals*. Princeton University Press, 2007.
14. **Louz D, et al.** Emergence of viral diseases: mathematical modeling as a tool for infection control, policy and decision making. *Critical Reviews in Microbiology* 2010; **36**, 195–211.
15. **Lavine JS, Poss M, Grenfell BT.** Directly transmitted viral diseases: modeling the dynamics of transmission. *Trends in Microbiology* 2008; **16**, 165–172.
16. **Atmar RL, et al.** Norovirus vaccine against experimental human Norwalk virus illness. *New England Journal of Medicine* 2011; **365**, 2178–2187.
17. **Reich NG, et al.** Visualizing clinical evidence: citation networks for the incubation periods of respiratory viral infections. *PLoS ONE* 2011; **6**, e19496.
18. **Lessler J, et al.** Incubation periods of acute respiratory viral infections: a systematic review. *Lancet Infectious Diseases* 2009; **9**, 291–300.
19. **Carrat F, et al.** Time lines of infection and disease in human influenza: a review of volunteer challenge studies. *American Journal of Epidemiology* 2008; **167**, 775–785.
20. **Lee RM, et al.** Incubation periods of viral gastroenteritis: a systematic review. *BMC Infectious Diseases* 2013; **13**, 446.
21. **Desai R, et al.** Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review. *Clinical Infectious Diseases* 2012; **55**, 189–193.
22. **Matthews JE, et al.** The epidemiology of published norovirus outbreaks: a review of risk factors associated with attack rate and genogroup. *Epidemiology and Infection* 2012; **140**. 1161–1172,
23. **Efron B, Tibshirani R.** *An Introduction to the Bootstrap.* Chapman & Hall, 1993.
24. **Schenker N, Gentleman JF.** On Judging the significance of differences by examining the overlap between confidence intervals. *The American Statistician* 2001; **55**, 182–186.
25. **Hastie T, Tibshirani R, Friedman J.** *The Elements of Statistical Learning: Data Mining, Inference, and Prediction*, 2nd edn, 2009 (corr. 7th printing 2013 edn). New York, NY: Springer, 2011.
26. **R Core Team.** *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing, 2013.
27. **O'Reilly CE, et al.** A waterborne outbreak of gastroenteritis with multiple etiologies among resort island visitors and residents: Ohio, 2004. *Clinical Infectious Diseases* 2007; **44**, 506–512.
28. **Siebenga JJ, et al.** High prevalence of prolonged norovirus shedding and illness among hospitalized patients: a model for in vivo molecular evolution. *Journal of Infectious Diseases* 2008; **198**, 994–1001.
29. **Nicholson KG, Wood JM, Zambon M.** Influenza. *Lancet* 2003; **362**, 1733–1745.
30. **Rockx B, et al.** Natural history of human calicivirus infection: a prospective cohort study. *Clinical Infectious Diseases* 2002; **35**, 246–253.
31. **Lopman BA, et al.** Clinical manifestation of norovirus gastroenteritis in health care settings. *Clinical Infectious Diseases* 2004; **39**, 318–324.
32. **Lopman B, et al.** Increase in viral gastroenteritis outbreaks in Europe and epidemic spread of new norovirus variant. *Lancet* 2004; **363**, 682–688.